Free Trial

Financial Gravity Asset Management Inc. Buys Shares of 45,064 Moderna, Inc. (NASDAQ:MRNA)

Moderna logo with Medical background

Financial Gravity Asset Management Inc. bought a new stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor bought 45,064 shares of the company's stock, valued at approximately $1,278,000.

A number of other institutional investors and hedge funds also recently modified their holdings of MRNA. Nisa Investment Advisors LLC grew its stake in Moderna by 166.9% in the 1st quarter. Nisa Investment Advisors LLC now owns 34,108 shares of the company's stock valued at $967,000 after buying an additional 21,330 shares during the last quarter. Moloney Securities Asset Management LLC grew its stake in Moderna by 933.2% in the 1st quarter. Moloney Securities Asset Management LLC now owns 50,150 shares of the company's stock valued at $1,422,000 after buying an additional 45,296 shares during the last quarter. New Insight Wealth Advisors grew its stake in Moderna by 17.3% in the 1st quarter. New Insight Wealth Advisors now owns 10,023 shares of the company's stock valued at $284,000 after buying an additional 1,478 shares during the last quarter. DekaBank Deutsche Girozentrale grew its stake in Moderna by 0.7% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 221,718 shares of the company's stock valued at $6,060,000 after buying an additional 1,473 shares during the last quarter. Finally, M&T Bank Corp grew its stake in Moderna by 7.0% in the 1st quarter. M&T Bank Corp now owns 19,008 shares of the company's stock valued at $539,000 after buying an additional 1,249 shares during the last quarter. 75.33% of the stock is owned by institutional investors.

Moderna Stock Performance

Shares of NASDAQ MRNA traded down $0.64 during trading hours on Friday, hitting $33.64. 6,916,105 shares of the stock were exchanged, compared to its average volume of 8,858,216. The company has a market cap of $13.01 billion, a PE ratio of -3.85 and a beta of 1.84. The company's fifty day simple moving average is $27.21 and its two-hundred day simple moving average is $31.21. Moderna, Inc. has a 1-year low of $23.15 and a 1-year high of $129.39.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.92) by $0.40. The business had revenue of $108.00 million for the quarter, compared to analyst estimates of $130.35 million. Moderna had a negative net margin of 105.67% and a negative return on equity of 28.69%. The firm's revenue for the quarter was down 35.3% on a year-over-year basis. During the same quarter last year, the business posted ($3.07) EPS. As a group, sell-side analysts expect that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. Barclays decreased their price target on shares of Moderna from $45.00 to $40.00 and set an "equal weight" rating on the stock in a research note on Friday, May 2nd. JPMorgan Chase & Co. decreased their price target on shares of Moderna from $33.00 to $26.00 and set an "underweight" rating on the stock in a research note on Thursday, May 22nd. William Blair reiterated a "market perform" rating on shares of Moderna in a research note on Monday, June 2nd. UBS Group decreased their target price on shares of Moderna from $78.00 to $70.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Finally, Royal Bank Of Canada decreased their target price on shares of Moderna from $32.00 to $28.00 and set a "sector perform" rating on the stock in a research report on Friday, May 2nd. Four equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $46.61.

Read Our Latest Analysis on MRNA

About Moderna

(Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

See Also

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Should You Invest $1,000 in Moderna Right Now?

Before you consider Moderna, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.

While Moderna currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Hot Growth Stocks to Watch Right Now!
Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines